AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 4.06M but it saw 4050552 shares traded in last market. With a market cap of 722.33M USD, the company’s current market price of $2.42 came rising about 4.76 while comparing to the previous closing price of $2.31. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.89 and as low as $1.89.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving 18.63% up while it is 10.50% when we observe its performance for the past one month. Year-to-date it is -17.41% down and over the past year, the stock is showing a downside performance of -38.27%.
The company is expected to be releasing its next quarterly report in July, for which analysts forecasted an EPS of -0.16 while estimate for next year EPS is -0.64. In next quarter, company is expected to be making quarterly sales of $7.57M as analysts are expecting the sales for current fiscal year at $26.06M and seeing the company making $52.58M in sales next year. Moreover, analysts are in estimates of $7.55M for current-quarter revenue.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 298.36M with 22.97% of that held by the insiders while 44.70% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -15.45% and return on equity (ROE) at -15.59%. Stock’s beta reads 0.36. Stock has a price to book (P/B) ratio of 0.71 while price to sale or P/S ratio amounts to 31.24. Its return on asset (ROA) is -11.96% on average.
